



China Pharmaceutical Guide

中国医药市场指南

9th Edition (2014)

Volume 1

Written by:

James J. Shen, MBA

Unrivaled China Healthcare Intelligence Since 1991

Published by WiCON International Group

WiCON International Group LLC

311 Sayre Drive, Princeton, NJ 08540, USA

Tel: +1 609 919 0898 Fax: +1 702 995 3905

Email: info@pharmachinaonline.com Internet: www.pharmachinaonline.com

China Office

Suite 17D, Building B, Oriental Kenzo Plaza

48 Dongzhimenwai Dajie, Dongcheng District, Beijing 100027, China

Tel: +86 10 8447 6010 Fax: +86 10 8447 6110

Email: info@pharmachinaonline.com

Disclaimer

While every effort has been made to ensure that information in this publication is correct, no liability can be accepted for any loss incurred in any way whatsoever by any company or individual relying on the information herein. To the best of our knowledge the information given is accurate at the date of publication.

Copyright © 2014 by WiCON International Group LLC

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means - electronic magnetic tape, mechanical, photocopying, recording or otherwise - without prior permission of the copyright owner.

ABOUT THE AUTHOR

China Pharmaceutical Guide is authored by James J. Shen, a veteran of the Chinese healthcare industry and market, who has dedicated his entire 27-year career to pharmaceutical businesses in China.

James Shen has rich operational and senior level management experience on China's healthcare businesses in the capacities of a senior consultant to multinational pharmaceutical companies, a manager of joint venture projects and companies, a business development executive, an entrepreneur, and most recently a publisher.



James Shen started his career in the pharmaceutical industry in 1987 when he joined Beijing Ciba-Geigy Pharmaceutical Ltd. (now Beijing Novartis) as Assistant to the General Manager. While he studied MBA in England in various periods of 1980s, he worked as an editorial consultant for Scrip/PJB Publications, IMS and Financial Times Business Information on China's healthcare news.

In 1991, he founded WiCON International Group in the USA to provide strategic consulting and competitive intelligence to international healthcare companies in order to assist and facilitate their market entry into China. He has worked with many large and mid-size international pharmaceutical companies on a diverse range of projects including entry strategy development, strategic alliances and joint ventures, marketing and distribution agreements, product registration and clinical trials, licensing and technology transfer, API sourcing, and M&A due diligence.

As an entrepreneur, James Shen co-founded *Beijing Jicai Pharmaceutical Technologies Ltd.* in 1992, one of the first private pharmaceutical research institutions in China, and took over its management in 2001. He is also a co-founder of *Nanjing Zinox Pharmaceutical Co. Ltd.*, an emerging generic pharmaceutical company in China.

James Shen was the Managing Editor of the well-known *IMS China Update*, a monthly newsletter covering China's pharmaceutical market co-published by IMS and WiCON. He authored many China healthcare business publications in English throughout 1990s, including *Marketing Pharmaceuticals in China*, *Guide to Pharmaceutical Research Institutions in China*, and *Directory of Bulk Pharmaceutical Manufacturers & Products in China*.

In early 2006, following a restructure of WiCON's businesses, James Shen founded ***Pharma China***, now the highly-respected English media and business intelligence service on China's pharmaceutical industry and market which is subscribed by almost all multinational pharmaceutical companies, CROs, consulting companies and investment banking firms active in China.

James Shen was educated in China, Europe and the USA at university and postgraduate

levels, and received an MBA from the University of Exeter (UK) in 1990.

He is now based in Princeton, New Jersey with frequent visits to China and Europe. He continues to be active in strategic consulting with multinational pharmaceutical companies at headquarter and regional head office levels.

PREFACE

Despite the enormous business opportunities and growth prospects offered by China's healthcare sector, I've witnessed and experienced countless regulatory and business environmental changes, which has frequently caused painful business difficulties, frustrations and downfalls, in my past 27 years of work in the sector as a consultant, manager and entrepreneur.

The ever-changing legal and market environments in China healthcare present the single biggest challenge to companies and executives operating in the sector. Naturally, many operational level issues and problems in the country also pose significant challenges to successful businesses.

In spite of these challenges and difficulties, the Chinese pharmaceutical industry and market have achieved remarkable growth in the past two decades. The sector is generally developing towards a positive direction in the sense that it continues to grow steadily, its regulatory regime has become increasingly compatible with international standards with improving transparency, once rampant corruption is being tackled, its ongoing consolidation will eventually help establish order and stability, and the country's new healthcare reform will ultimately led to a more stable and healthier market environment.

There are success stories from all categories of players, whether they are foreign or local, large or small, newcomer or established, private or state-owned. However, to be one of the success stories require a thorough understanding of the sector, ability to face and tackle challenges, flexibility to deal with changes, and skills to maneuver through complex situations.

It has been my wish to put my experience and observations in the past 27 years of operating in almost every aspect of China's pharmaceutical business into a publication, which will serve as a one-stop reference to anyone seeking to enter or operate in the Chinese pharmaceutical market. As of our 2007 edition, we have been adding a rising number of commentaries and contributions from many other leading pharma industry executives and experts.

Packed with hard-to-find current data and the author's expert knowledge from years of hard-earned experience in the industry, its comprehensiveness, practicality, insight, reliable data and analysis, and up-to-date information, are the features which set this the guide apart from other publications with similar titles.

This Guide is written based on my past experience, interviews with relevant industry experts and government officials, articles from Pharma China, information obtained from or published by Chinese government agencies, information obtained from or published by independent pharmaceutical industry associations, reliable data and information released exclusively to WiCON for publication from various reputable market research and consulting firms, information from other trustworthy trade journals and newspapers, related information found on the internet, and a large in-house information collection by

WiCON International Group accumulated since 1991.

About China Pharmaceutical Guide 2014 (9th Edition)

The China Pharmaceutical Guide 2014 (9th Edition) has been thoroughly updated with ample latest data from many reputable sources, abundant analysis by leading industry experts, new regulations and more case studies. Its coverage was renewed and expanded significantly in the following areas:

- ☞ Hundreds of pages of new data, information, analysis and case studies.
- ☞ Thorough summaries and analysis of the latest healthcare reform, drug pricing & reimbursement and hospital tender purchase policies.
- ☞ Comprehensive industry, market and international trade data as well as health statistics are updated with the 2013 (full year) and early 2014 figures.
- ☞ Expanded coverage on the primary healthcare sector, the OTC and consumer healthcare sector, high growth market segments, key regional hospital markets, the pharmaceutical distribution sector and online retail pharmacy segment.
- ☞ Updated coverage of the Chinese biosimilar market prospects and regulatory outlook.
- ☞ Updated coverage of emerging legal issues (including latest Chinese government crackdown on corruption in healthcare, FCPA/compliance and liability issues) and drug-related IP and trademark concerns.
- ☞ Comprehensive top line data, research findings and observations from our collaborative partners such as IMS Health, Kantar Health, Nicholas Hall, ZS Associates and RDPAC, as well as other reputable sources including the Chinese Pharmaceutical Association, SMEI and Sinohealth.
- ☞ All regulatory changes in 2013/2014 are updated to present a clear and most up-to-date picture of the Chinese drug regulatory framework with summaries and analysis of all drug regulations in effect by mid-2014.
- ☞ Focused coverage of China's deepening reform of its drug registration and evaluation regime, new policies to support drug innovation and high clinical value generics, and its initiative to re-evaluate all generic drugs with bioequivalence studies.
- ☞ An updated section covering proposed new drug-related laws and regulations under drafting process with previews of the draft versions.
- ☞ Extensive review and analysis of China's drug registration applications and approvals as well as Chinese drug innovation trends in recent years.

- ☞ Comprehensive review of Sino-foreign M&A, joint venture, strategic alliance, licensing, research partnerships, co-marketing, and new drug research events in 2013 and early 2014.
- ☞ Expanded coverage on MNC strategies in China with healthcare reform in the backdrop, intellectual property/patent law amendments, data exclusivity, patent litigation, drug regulations, pharma marketing and distribution strategies, drug consumption patterns, the Chinese R&D and outsourcing sector, clinical studies/practices, healthcare reform, community healthcare sector, essential drug policy, regional drug consumption patterns, and the vaccine and API sectors.
- ☞ Numerous new case studies are added to the 2014 Edition.
- ☞ Comprehensive revision of the China operation profiles of MNCs to reflect their latest performance, business deals, legal disputes and outlook.

I would like to take the opportunity to thank all those organizations and individuals who contributed to this publication and their continued cooperation is greatly appreciated.

James J. Shen

June 30, 2014

This Page is Left Blank Intentionally

TABLE OF CONTENTS

ABOUT THE AUTHOR	3
PREFACE	5
TABLE OF CONTENTS	9
LIST OF TABLES	17
LIST OF CHARTS	27
TABLE OF ABBREVIATIONS	32
EXECUTIVE SUMMARY	35
PART I OVERVIEW OF THE CHINESE ECONOMY AND BUSINESS	49
Chapter I-1 Introduction	51
1.1 Fast Economic Growth and Change	51
1.2 Integration into the World Economy.....	52
1.3 Economic Reform.....	53
1.4 WTO Entry Brought Further Reform and Regulatory Changes.....	54
1.5 Rising R&D Investments and Patent Applications	56
1.6 China's R&D Spending Projected to Surpass EU in 2019 and the US in 2022	60
1.7 Increasing Intellectual Prowness of China in Global Life Science	61
Chapter I-2 Demographic Trends	63
2.1 Land and People	63
2.2 Demographic Trends.....	63
2.3 The Chinese Consumer Landscape.....	69
2.4 Conclusion – China Faces Daunting Demographic Challenges.....	77
Chapter I-3 Contemporary Issues and Trends	80
3.1 Review of Chinese Economy in 2013.....	80
3.2 Major International Trade Issues	82
3.3 Contemporary Social-Economic Issues and Challenges Facing China.....	85
3.4 Outlook - The Chinese Economy Faces Mounting Uncertainties and Complex Challenges	88
Chapter I-4 FOREIGN INVESTMENT: Structure, Trends & Outlook	95
4.1 Overview	96
4.2 Chinese Legal System.....	97
4.3 Foreign Investment Regulatory Framework	98
4.4 Major Tax Categories for FIEs and Foreigners.....	110
4.5 Business Climate and Outlook – Surveys of Foreign Companies in China	112
PART II THE CHINESE PHARMACEUTICAL INDUSTRY AND MARKET 119	
Chapter II-1 Introduction	121
1.1 Definitions and Coverage	121
1.2 Segmentation of the Chinese Pharmaceutical Industry.....	122

1.3	A Brief History of the Modern Chinese Pharmaceutical Industry	124
1.4	A Brief History of Drug Industry Administration and Regulation in China	125
1.5	Government Guidelines for Pharmaceutical Industry Development.....	127
1.6	The Size of the Chinese Pharmaceutical Market	135
1.7	Future Outlook of the Chinese Pharmaceutical Industry and Market	138
Chapter II-2 The Pharmaceutical Industry		142
2.1	Overview of the Chinese Pharmaceutical Industry	142
2.2	The Pharmaceutical Manufacturing Sector	149
2.3	The Biopharmaceutical Sector	155
2.4	The Pharmaceutical Distribution Sector	164
2.5	The Human Vaccine Sector	170
2.6	R&D of the Domestic Chinese Pharmaceutical Industry	177
2.7	Pharmaceutical R&D in China – Foreign Companies.....	184
2.8	Pharmaceutical Outsourcing Sector (R&D and Manufacturing).....	189
2.9	M&A and Consolidation in the Chinese Pharmaceutical Industry.....	194
2.10	Leading Pharmaceutical Companies in China	198
2.11	Leading Retail Pharmacy Chains in China.....	206
Chapter II-3 Foreign Investment in the Pharma Industry		209
3.1	Forms of Foreign Investment	209
3.2	Encouraged, Restricted and Banned Areas for Foreign Investment in the Pharma Industry....	209
3.3	Growth of Foreign Investment	213
3.4	Contemporary Trends, Issues and Strategic Considerations for Foreign Investment in the Pharmaceutical Industry	218
3.5	Strategic considerations for MNCs	226
3.6	China’s Healthcare FDI Challenge.....	229
Chapter II-4 Intellectual Property Rights and Legal Issues		232
4.1	Pharmaceutical Patent Protection.....	235
4.2	Administrative Protection of Pharmaceuticals (APP).....	255
4.3	Data Exclusivity.....	261
4.4	Patent and Trademark Registration	263
4.5	Protecting and Policing IPRs in China.....	267
4.6	Patent and IP Strategies for China.....	268
4.7	Pharmaceutical Patent Litigation in China.....	270
4.8	China: China's Evolving Legal Landscape For Trade Secret Protection.....	275
4.9	Counterfeit Drugs.....	277
4.10	New Judicial Interpretation of Guidelines for Applying Criminal Law to Fake Drug and Inferior Drug Cases.....	280
4.11	The PRC's New Tort Liability Law: What Can Pharmas Expect?	285
4.12	Chinese Courts See Fast Growing Lawsuits over Food and Drug Safety	289
4.13	Navigating Compliance Risks When Donating to and Sponsoring Medical Institutions in China	290

4.14	In the Chase for Market Share, Pharmaceutical Companies Need Comprehensive Measures to Reduce Corruption Risk in China.....	292
4.15	GSK and Missed Red Flags in China.....	295
4.16	Will GSK’s incentive compensation and speaker program initiatives set the tone for 2014? 299	
4.17	How China's Anti-Monopoly Laws Could Impact the Pharmaceutical Sector	301
Chapter II-5 The Ethical Pharmaceutical Market.....		304
5.1	Market Size.....	304
5.2	Growth Forecast and Future Outlook.....	305
5.3	Special Characteristics of the Chinese Ethical Pharmaceutical Market.....	307
5.4	The Hospital Sector	308
5.5	The Rise of Retail Pharmacy Sector	310
5.6	Ethical Pharmaceutical Market: Urban vs. Rural.....	318
5.7	Rising Importance of the Primary Healthcare Drug Market.....	320
5.8	TCMs Presents Challenge to MNC Growth in China	323
Chapter II-6 The Chinese Vaccine Market		325
6.1	Market Landscape.....	325
6.2	Snapshot of Hospital Vaccine Sales in 22 Chinese Cities Since 2006	328
6.3	Market Outlook of the Chinese Human Vaccine Market	331
6.4	Asia Pacific Vaccine Market Requires Flexible, Targeted Portfolios.....	331
Chapter II-7 The OTC Pharmaceutical Market		333
7.1	OTC Market Size.....	333
7.2	Regulatory Progress on OTC Drugs	337
7.3	Chinese OTC Drug Market Growth Bottlenecked by Various Challenges Despite Rising Trend of Self-medication.....	339
7.4	Enthusiastic Pharmaceutical Industry Seeks to Expand OTC Drug Sales	341
7.5	MNCs Strive for OTC Growth in China.....	342
7.6	Pharma Companies Turn to Consumer Healthcare for Higher Return.....	347
7.7	Healthcare Reform Casts Shadow on Future of the Retail Pharmacy Sector.....	348
7.8	Chinese Online Pharmacy Sales on the Rise Despite Uncertainties Ahead	348
7.9	CFDA Considers Ban of OTC Drug Ads on Mass Media.....	350
Chapter II-8 The Bulk Drug/API sector		352
8.1	Overview	352
8.2	International Regulatory Compliance	355
8.3	Technological Strength	357
8.4	Comparisons with India’s API industry	358
8.5	Rising Power of China’s API Industry.....	361
8.6	Recent Trends and Challenges.....	362
8.7	Outlook of the API Industry and Market in China and Asia Pacific	364
8.8	China Remains A Challenge to the USFDA Despite Opening Three Field Offices.....	366
Chapter II-9 Pharmaceutical Import and Export.....		368

9.1	Overview.....	368
9.2	Custom Duties on Drug Import.....	370
9.3	Import of WMs and MHPs.....	370
9.4	Export of MHPs and Western Medicines.....	372
9.5	Trends and Outlook for Western Medicine Foreign Trade.....	374
9.6	China and India Sought to Join Hands for Supply to the Global Drug Market.....	375
9.7	China Raises Activities in Regulated Markets.....	376
PART III PHARMACEUTICAL REGULATORY FRAMEWORK.....		383
Chapter III-1 Overview.....		385
1.1	Drug Regulation Statistics.....	385
1.2	Overview of Drug Evaluation and Registration.....	386
1.3	Adverse Drug Reaction Surveillance and Reporting.....	390
1.4	Review of New Chinese Pharmaceutical/Healthcare Regulations in 2013.....	393
1.5	Major Drug-related Regulations and Laws under Drafting Process.....	395
1.6	Drug Regulatory Direction in 2014.....	398
1.7	New Policy for Reform of China's Drug Registration Regime.....	400
1.8	CDE Initiates Development of Technical Guidelines for Registration of Biosimilars.....	404
1.9	CFDA Issues Plan to Phase in Bioequivalence Study on Generic Drugs.....	404
1.10	Reorganization of the Chinese Healthcare Agencies.....	407
1.11	Major Pharma Regulatory Changes Proposed in China.....	408
Chapter III-2 Important Laws and Regulations.....		412
2.1	The Drug Administration Law of the People's Republic of China.....	412
2.2	Regulations for Implementation of the Drug Administration Law of the PRC.....	413
2.3	Major Regulations Governed under the <i>Drug Administration Law (2001)</i>	413
2.4	Other Drug Related Laws and Regulations.....	416
Chapter III-3 Major Government Agencies in the Pharma Field.....		418
3.1	The China Food and Drug Administration (CFDA).....	418
3.2	The Center for Drug Evaluation under the CFDA.....	428
3.3	National Development and Reform Commission (NDRC).....	430
3.4	The National Health and Family Planning Commission (NHFPC).....	434
3.5	Ministry of Human Resources and Social Security (MOHRSS).....	441
3.6	Ministry of Industry and Information Technology (MIIT).....	442
3.7	Ministry of Commerce (MOFCOM or MOC).....	443
3.8	State-owned Assets Supervision and Administration Commission (SASAC).....	444
3.9	State Administration of Traditional Chinese Medicine (SATCM).....	445
Chapter III-4 Pharmaceutical Industry Associations in China.....		446
Chapter III-5 Drug Regulatory Framework in China.....		450
5.1	Pharmaceutical Manufacturer Licensing.....	450
5.2	Contract Manufacture/OEM.....	454
5.3	Pharmaceutical Manufacturing and GMP Certification.....	458

5.4	Regulation of Pharmaceutical Excipients	463
5.5	Drug Labeling and Packaging.....	468
5.6	Pharmaceutical Distribution Licensing.....	473
5.7	Pharmaceutical Distribution.....	476
5.8	Registration of Domestic/Imported Drug and Biological Products	480
5.9	Drug Import Process	503
5.10	Classified Control of Drug Products.....	507
5.11	Drug Advertising.....	510
5.12	Drug Pricing and Price Control.....	516
5.13	Post-marketing Surveillance/ADR Reporting.....	540
5.14	Counterfeit, Fake and Sub-standard Drugs	547
5.15	Control of Narcotics and Psychotropic Drugs	554
5.16	Internet Information Service and Sales of Drug Products.....	556
5.17	Drug Prescription/Surveillance of Rational Drug Use/Clinical Practices	559
5.18	GLP/Non-clinical Research and GCP/Clinical Research.....	570
5.19	Electronic Regulation of Drugs	574
5.20	Pharmaceutical Technology Transfer / Administrative Protection / IP	577
5.21	Anti-corruption/Compliance/Black Listing/Drug Donation	581
5.22	International Regulatory Cooperation.....	587
5.23	Others.....	590
PART IV HEALTHCARE PROVISION AND FINANCING.....		595
Chapter IV-1 Overview.....		597
1.1	Improving Healthcare Provision	597
1.2	Falling Death Rate and Rising Life Expectancy	599
1.3	Composition of the Chinese Population.....	601
1.4	Economic Burden from Chronic Diseases May Slowdown China's Growth.....	603
1.5	2013 Annual Health and Family Planning Sector Development Report.....	604
1.6	MOH's Health China 2020 Strategic Research Report.....	608
Chapter IV-2 Structure and Composition of Medical Provision.....		610
2.1	Composition of the Chinese Medical Sector.....	610
2.2	Grade Structure of Chinese Medical Institutions	613
2.3	Regional Distribution of Healthcare Resources	614
2.4	Distribution of Healthcare Resources by Medical Specialty	618
2.5	Human Resources in China's Healthcare Industry.....	619
2.6	China Seeks to Establish a General Practitioner System by 2020	621
2.7	MOH Encourages the Formation of Medical Service Consortiums.....	622
Chapter IV-3 Healthcare Reform		624
3.1	A Review of China's Healthcare System Reform in the Past Three Decades.....	624
3.2	Details of the Healthcare Reform Plan	626
3.3	Primary Healthcare Reform Areas Between 2011 and 2015.....	632
3.4	The Healthcare Reform Plan in the 12 th FYP (2011-2015).....	633

3.5 Latest Developments - Healthcare Reform in Stalemate and Primarily Driven by Cost Containment.....	639
3.6 Healthcare Reform Outlook in 2014 and Beyond.....	646
Chapter IV-4 Healthcare Financing and Insurance Programs.....	652
4.1 Healthcare Financing in China.....	652
4.2 Urban Employee Basic Medical Insurance.....	657
4.3 Urban Resident Basic Medical Insurance Program.....	659
4.4 Work-related injury insurance Program.....	660
4.5 Medical Assistance Program for Civil Servants.....	661
4.6 New Rural Cooperative Medical Scheme (NRCMS).....	662
4.7 Major Medical Insurance Coverage for Urban and Rural Residents.....	663
4.8 Maternity Insurance.....	666
4.9 Medical Assistance Program for the Poor.....	668
4.10 Commercial Health Insurance.....	669
4.11 Universal Coverage of Chinese Population by Basic Medical Insurance.....	673
4.12 China's Health Protection Gap to Reach US\$73B by 2020.....	675
Chapter IV-5 Drug Reimbursement.....	677
5.1 Drug Reimbursement under BMI, WRI and MI Programs.....	677
5.2 A Summary of the MoHRSS Notice for Publication of the 2009 NDRL under BMI, WRI and MI Programs.....	679
5.3 Common Rules (凡例) of the 2009 NDRL under BMI, WRI and MI Programs.....	682
5.4 Drug Reimbursement under the New Rural Cooperative Medical System.....	685
5.5 The Proposed Negotiation Mechanism under the NDRL and NRCMS.....	686
5.6 Observations and Discussions on Drug Reimbursement in China.....	687
Chapter IV-6 Measures of Medical Cost-containment.....	689
6.1 Price Control.....	690
6.2 Centralized Hospital Drug Purchase Tenders.....	693
6.3 The National Essential Drug System.....	706
6.4 National Formulary and Clinical Guidelines.....	714
6.5 Clinical Pathway/DRGs.....	715
6.6 Other Cost-containment Measures.....	716
6.7 China's Universal BMI System Faces the Double-bladed Sword of Potential Deficits and Excessive Cost Containment.....	719
PART V DISEASE AND DRUG CONSUMPTION PATTERNS.....	723
Chapter V-1 Growth of Drug Consumption and Demand.....	725
1.1 Sharp Growth in Drug Consumption and Healthcare Expenditures.....	725
1.2 The State of Health of the Chinese Population.....	730
1.3 Health Awareness and Literacy.....	731
1.4 Aging Population and Increased Demand on Healthcare In China.....	732
1.5 Medical and Public Health Services.....	735

Chapter V-2 Popular Diseases and Morbidity	736
2.1 Leading Diseases in Recent Years	736
2.2 Leading Causes of Death	740
2.3 An Extensive Overview of Chronic and Epidemic Diseases in China.....	743
2.4 Recent Chinese Therapeutic Trends in Diabetes, Hepatitis B and Oncology	757
2.5 Prevalent Health Problems to Senior Citizens in China.....	768
2.6 Chinese in Good Health Longer Than People in Other G20 Countries	769
Chapter V-3 Hospital Attendance and Medical Expenses	771
3.1 Composition of Medical Care System in China.....	771
3.2 Hospital Attendance.....	772
3.3 Healthcare Expenditures and Medical Expenses	775
Chapter V-4 Hospital Drug Consumption Patterns	782
4.1 Market Trends of the Chinese Hospital Drug Market in 2012.....	782
4.2 Leading Drug Products in Urban Hospitals	785
4.3 Leading Pharmaceutical Suppliers.....	790
4.4 Patterns of Hospital Drug Purchase by Therapeutic Classes	793
4.5 High Growth Market Segments	797
Chapter V-5 Retail Drug Consumption Patterns	817
5.1 Review of the Chinese Retail Pharmacy Market	817
5.2 Patterns of Retail Pharmacy Sales of Medicine and Health Products.....	818
5.3 Structure of Chinese B2C Online Pharmacy Market	836
Chapter V-6 Consumption Patterns of OTC Drugs	840
6.1 Structure of Chinese OTC Drug Sales	840
6.2 Leading Chinese OTC Companies and Brands.....	843
6.3 How to Succeed in China's Challenging OTC Environment	846
Chapter V-7 Consumption Patterns of Formulated Traditional Chinese Medicines	850
7.1 IMS Data.....	850
7.2 SMEI Data	853
7.3 Sinohealth Data.....	853
Chapter V-8 Regional Drug Consumption Patterns.....	855
8.1 Gap Between Cities and Rural Areas.....	855
8.2 Regional Hospital Markets for Drug Products.....	856
8.3 Regional Markets by Pharmaceutical Distributor Sales.....	863
8.4 Regional Retail Pharmacy Markets for Drug Products.....	863
8.5 Regional OTC Drug Markets.....	866
8.6 Regional Primary Healthcare Drug Markets.....	868

Chapter V-9 Market Shares of Local, JV and Imported Drugs	872
9.1 Hospital Market – Local vs. JV vs. Imported Drugs.....	872
9.2 Retail Pharmacy/OTC Market - Domestic Companies vs. JV/Foreign Players	878
9.3 Market Segmentation by New and Generic Drugs.....	881
9.4 Leading Multinational Pharmaceutical Companies in China.....	882
9.5 Future Trends and Outlook	883

LIST OF TABLES

Table 2.1 Overall Chinese Drug Market Size and Growth 2007-2013	135
Table 2.2a Chinese Drug Market Size by Major Segments 2001-2015	136
Table 2.2b Chinese Drug Market Size Projections by Major Segments 2013-2015	137
Table 2.3a Chinese Drug Market Shares by Sub-segments 2003-2011	137
Table 2.3b Chinese Drug Market Shares by Sub-segments 2012-2015	138
Table 2.4 Number of Pharmaceutical Businesses in China Since 1997	142
Table 2.5 Biopharma Players in Top 100 Chinese Pharma Cos 2006-2011	156
Table 2.6 Chinese Foreign Trade of Biopharmaceutical Products 2007-2013	159
Table 2.7 Regional Export Markets for Biopharmaceuticals in 2012	160
Table 2.8 Chinese Approvals for New Biological Formulations 2007-2011*	160
Table 2.9 Chinese Approvals of Biological Products by TCs 2007-2011*	160
Table 2.10 Outcome of Registration Applications for Biological Products in 2012	161
Table 2.11 Regional Pharmaceutical Distributor Sales Structure 2013	168
Table 2.12 Top 10 Chinese Pharma Distributors by Sales in 2013	169
Table 2.13 Top 10 Chinese Retail Companies by Sales Revenues in 2013	170
Table 2.14 New Vaccine Products under Development by MNCs in China	172
Table 2.15 R&D Centers of RDPAC Members in China	186
Table 2.16 Top 20 Chinese Pharma Companies by Total Assets in 2013	198
Table 2.17 Top 20 Chinese Pharma Companies by Sales Revenues in 2013	199
Table 2.18 Top 20 Chinese Pharma Companies by Net Profit in 2013	199
Table 2.19 Best Chinese Pharma Manufacturers by R&D Pipelines 2013	201
Table 2.20 Best Chinese Pharma Companies by Investment Value 2013	201
Table 2.21 Top 20 Chinese Pharmaceutical Companies by Sales in 2011-2013	202
Table 2.22 Top 10 Chinese Pharma Companies by Sales Growth in 2013	203
Table 2.23 Top 10 Chinese Pharma Companies by Profit Growth in 2013	203
Table 2.24 Revenue Size of Top 100 Chinese Pharma Companies 2006-2013	204
Table 2.25 Revenue Size of the Top 100 Chinese Pharma Companies in 2013	204

Table 2.26 Publicly-listed Firms in Top 100 Chinese Pharma Companies by Sales 2009-2013	204
Table 2.27 Subsectors of Top 100 Chinese Pharma Companies by Sales in 2013	204
Table 2.28 Regional Distribution of Top 100 Chinese Pharma Companies by Sales in 2013	205
Table 2.29 Top 20 Listed Companies by Revenue in 2013	206
Table 2.30 Top 20 Chinese Retail Pharmacy Chains 2013	206
Table 2.31 Top 10 Chinese Retail Pharmacy Chains by Overall Competitiveness in 2013	207
Table 2.32 First Ten Sino-Foreign Pharmaceutical Joint Ventures in China	215
Table 2.33 Foreign Investment in the Chinese Pharmaceutical Industry in the 1990s ..	215
Table 2.34 Pharma Foreign Investments in China between 2000 and 2006	216
Table 2.35 Market Shares of 3T and Community Healthcare Markets Since 2003.....	321
Table 2.36 # of Outpatient Visits and Inpatients by Medical Institution Types 2008-2012	322
Table 2.37 Chinese Vaccine Market 2006-2014	326
Table 2.38 Market Shares of Chinese and Foreign Vaccines Companies by Volume*..	326
Table 2.39 Market Shares of Chinese and Foreign Vaccines Companies by Value.....	326
Table 2.40 Top Ten Vaccines by Sales in Rep Hospitals of 22 Chinese Cities 2010.....	328
Table 2.41 Growth of Retail Pharmacies 2010-2012 (27 Major Cities)	335
Table 2.42 Top 10 Chinese OTC Marketers 2011.....	343
Table 2.43 Growth of the Chinese API/Bulk Drug Sector 2002-2012	352
Table 2.44 Chinese APIs Export 2009 - 2013.....	353
Table 2.45 Chinese API Export Structure by Ownership Type in M1-7/2013	353
Table 2.46 Top 10 Chinese APIs Exporters in M1-7/2013	353
Table 2.47 Regional Export Markets for Chinese APIs in M1-7/2013.....	354
Table 2.48 Top 10 Country Markets for Chinese API Export in M1-7/2013.....	354
Table 2.49 China-based Pharma Companies with U.S. DMFs	355
Table 2.50 Summary of U.S. DMFs Filed Products Manufactured in China	356
Table 2.51 Top 15 China-based DMF holders with Ten or More Active DMFs.....	356

Table 2.52 Cost Comparisons: China vs. India vs. Europe vs. U.S.	360
Table 2.53 Chinese Foreign Trade of Medicines and Health Products in 2013 (US\$ mln)	370
Table 2.54 Major Categories of Western Medicine Import Since 2003 (US\$ million)..	371
Table 2.55 Chinese Import of MHPs by Categories in 2013 (US\$ mln)	371
Table 2.56 Chinese MHP Import by Region in 2013 (US\$ mln).....	371
Table 2.57 Chinese Export of MHPs by Categories in 2013 (US\$ mln)	372
Table 2.58 Regional Export Markets for Chinese MHPs in 2013 (US\$ mln).....	373
Table 2.59 Top 10 Exported Markets of Chinese MHPs in 2013.....	373
Table 3.1 Chinese Drug Approvals in 2013	387
Table 3.2 Chinese Drug Approvals in 2009-2013	387
Table 3.3 Breakdown of Clinical Trial Approvals in 2010-2013	388
Table 3.4 Review Outcome of Chemical Drug Registration Applications in 2013	388
Table 3.5 Chemical Drug Evaluation Wait-time by Registration Type in 2012-2013 ...	389
Table 3.6 Evaluation Timeframe for Clinical Trial Applications of Chemical Drug TCs 2013.....	389
Table 3.7 Review Outcome of TCM Registration Applications in 2013	390
Table 3.8 Review Outcome of Registration Applications for Biological Products in 2013	390
Table 3.9 Quarterly Pharma-Related Regulatory Introductions in China in 2010 - 2013	394
Table 3.10 New Pharma-Related Regulations and Policies Issued in 2013.....	394
Table 3.11 Differential/Relative Ratios for Common Formulations of Chemical Drugs & Biologicals (Appendix I).....	534
Table 3.12 Differential/Relative Ratios for Common Formulation of TCMs and Natural Drugs (Appendix II).....	535
Table 4.1 Improvement of Medical Provision in China	597
Table 4.2 Comparisons of Healthcare Provision by China vs. Other Countries (1)	598
Table 4.3 Comparisons of Healthcare Provision by China vs. Other Countries (2)	598
Table 4.4 Birth, Death and Population Natural Growth Rate.....	599

Table 4.5 Rising Life Expectancy of the Chinese Population	600
Table 4.6 Composition of the Chinese Population by Urban/Rural Division and Sex ..	601
Table 4.7 Composition of the Chinese Population by Age	602
Table 4.8 Composition of the Chinese Population by Education	602
Table 4.9 Medical Institutions by Specialties and Affiliations	611
Table 4.10 Inpatient Beds of Medical Institutions by Specialties and Affiliations.....	612
Table 4.11 Medical Institutions by Ownership Type	613
Table 4.12 Inpatient Beds of Medical Institutions by Ownership Type.....	613
Table 4.13 Inpatient Beds of Medical Institutions by Hospital Grade.....	613
Table 4.14 Number of Medical Institutions by Grade in 2012	614
Table 4.15 Regional Population Distribution in China 1990-2012.....	614
Table 4.16 Regional Distribution of Medical Institutions and Inpatient Beds in 2012 .	615
Table 4.17 Regional Distribution of Healthcare Professionals in 2012.....	617
Table 4.18 Distribution of Inpatient Beds by Medical Specialty 2005-2012	618
Table 4.19 Distribution of Physicians by Medical Specialty 2000-2012.....	619
Table 4.20 Healthcare Personnel in China 1950-2012.....	620
Table 4.21 Distribution of Healthcare Professionals in Cities and Counties 1980-2012	620
Table 4.22 Makeup of Healthcare Expenditures in China between 1980 and 2012	655
Table 4.23 Overview of Medical Assistance Coverage in Urban & Rural Areas	668
Table 4.24 Coverage of Chinese Population by Basic Medical Insurance (MIn).....	674
Table 4.25 Coverage and Finance of Urban BMI Programs.....	674
Table 4.26 Coverage/ Finance of New Rural Cooperative Medical System	674
Table 4.27 Summary of Drug Price Initiatives in China 1997-2013	691
Table 4.28 Consumer and Retail Price Indexes for Medicines & Health Products	693
Table 4.29 NEDL Product Definition Change: 2012 Ed. vs. 2009 Ed.....	709
Table 4.30 NEDL Structural Changes: 2012 Ed. vs. 2009 Ed.	709
Table 4.31 NEDL Changes by WM Therapeutic Classes: 2012 Ed. vs. 2009 Ed.....	709
Table 4.32 NEDL Changes by TCM Therapeutic Classes: 2012 Ed. vs. 2009 Ed.	710

Tabel 4.33 112 Newly Added Drugs (Chemical Drugs and Biologicals) in NEDL 2012 Ed.	711
Table 4.34 Chemical Drugs with Newly Added/Reduced Routes/Forms in NEDL 2012 Ed.	712
Table 5.1 Growth of Drug Consumption in China 2001-2013.....	725
Table 5.2 Growth of Healthcare Expenditures in China 1980-2013	725
Table 5.3 Rising Share of Per Capita Drug Expenditures in Healthcare.....	728
Table 5.4 Structure of Chinese Terminal Drug Sales Channel 2011-2012.....	730
Table 5.5 Chinese Drug Consumption by Terminal Market 2007-2012	730
Table 5.6 Percentage of Population Living in Urban / Rural Environs.....	733
Table 5.7 Leading Diseases by Two-week Morbidity in 2003.....	737
Table 5.8 Leading Diseases by Two-week Morbidity in 2008.....	738
Table 5.9 Morbidity Rate of Chronic Diseases in 2003 and 2008	738
Table 5.10 Trend of Leading 10 Diseases among Inpatients of Urban Hospitals 2000-2012	739
Table 5.11 Leading 10 Diseases among Inpatients of County Level Hospitals 2000-2012	740
Table 5.12 Leading Causes of Death in Certain Regions of China in 2012.....	741
Table 5.13 Leading Causes of Death among Chinese Males in 2012	741
Table 5.14 Leading Causes of Death among Chinese Females in 2012	742
Table 5.15 Examples of Drugs Covered under 2009 NRDL.....	763
Table 5.16 Drugs Covered under Pap Program in China 2011	764
Table 5.17 Composition of Medical Care Providers in China 1980-2012.....	771
Table 5.18 Number of Outpatient Visits and Inpatients in Medical Institutions 1980-2013	772
Table 5.19 Outpatient Visits and Inpatients by Medical Institution Type in 2012-2013	773
Table 5.20 Number of Outpatient Visits and Inpatients by Medical Specialties in 2012	773
Table 5.21 No. of Outpatient & Emergencies Visits by Medical Specialties 2011-2012	774
Table 5.22 Average Days of Hospitalization 1985-2012.....	774

Table 5.23 Income & Expenditure of Hospitals in 2012	775
Table 5.24 Per Capita Outpatient Medical Expense in Public Hospitals 2007-2012.....	776
Table 5.25 Per Capita Inpatient Medical Expense in Public Hospitals.....	777
Table 5.26 Per Capita Outpatient Medical Expense in Health Sector General Hospitals	778
Table 5.27 Per Capita Inpatient Medical Expense in Health Sector General Hospitals	779
Table 5.28 Outpatient and Inpatient Healthcare Expenditures in China 2009-2012 (CNY)	781
Table 5.29 Quarterly Sales of Chinese Hospital Market 2012-2013 (CNY mln)	782
Table 5.30 Quarterly Chinese Hospital Drug Sales of MNCs 2012-2013 (CNY mln)...	782
Table 5.31 Quarterly Chinese Hospital Drug Sales of Domestic Cos 2012-2013 (CNY mln)	783
Table 5.32 Chinese Hospital Drug Market Structure in 2013.....	783
Table 5.33 Value Segmentation of the Chinese Pharma Market by Sales Channels 2012	783
Table 5.34 Medical Institution Drug Consumption by Facility Type 2007-2013	784
Table 5.35 Top 10 Drug Brands by Hospital Purchase Value in 2013	785
Table 5.36 Top 10 Systemic Anti-infectives in Chinese Hospitals 2013	785
Table 5.37 Top 10 Oncology & Immuno-Regulatory Agents in Chinese Hospitals 2013	786
Table 5.38 Top 10 Cardiovascular System Drugs in Chinese Hospitals 2013.....	786
Table 5.39 Top 10 Digestive System Drugs in Chinese Hospitals 2013.....	787
Table 5.40 Top 10 Blood & Blood-making System Drugs in Chinese Hospitals 2013.	787
Table 5.41 Top 10 Nervous System Drugs in Chinese Hospitals 2013	787
Table 5.42 Top 10 Musculo-Skeletal System Drugs Shares in Chinese Hospitals 2013	788
Table 5.43 Top 10 Respiratory System Drugs in Chinese Hospitals 2013	788
Table 5.44 Top 10 Hormonal Drugs Systemic Drugs in Chinese Hospitals 2013	789
Table 5.45 Top 10 Reproductive/Urinary System and Sex Hormones Drugs in Chinese Hospitals 2013	789
Table 5.46 Top 15 Products in Chinese Rural Primary Healthcare by Sales Value	790

Table 5.47 Top 20 Chinese Pharma Cos by Hospital Drug Sales in 2013	790
Table 5.48 Top 20 Domestic Chinese Pharma Cos by Hospital Drug Sales in 2013.....	791
Table 5.49 Top 10 Hospital Drug Suppliers by Sales in 2013	792
Table 5.50 Top 15 Suppliers to Chinese Rural Primary Healthcare by Sales Value	792
Table 5.51 Top Ten Therapeutic Classes in 2013 by Hospital Drug Purchases	793
Table 5.52 Changing Hospital Drug Consumption Patterns 2006-2013	793
Table 5.53 Chinese Urban Hospital Drug Consumption by TCs 2012-2013	794
Table 5.54 Urban Hospital Drug Consumption by TCs 2012: WMs vs. TCMs	795
Table 5.55 Urban Primary Healthcare Drug Consumption by TCs 2012: WMs vs. TCMs	796
Table 5.56 County Level Hospital Drug Consumption by TCs 2012: WMs vs. TCMs.	796
Table 5.57 Chinese Rural Healthcare Drug Consumption by TCs.....	797
Table 5.58 Max Retail Prices of Top 10 Traditional Oncology Drugs in China	800
Table 5.59 Drug Consumptions in 263 Rep Hospitals of Six Chinese Cities 2012	801
Table 5.60 Top 20 Anticancer Drugs by Sales in 119 Shanghai Rep Hospitals 2012	801
Table 5.61 Top 20 Anticancer Drugs by Sales in 26 Hangzhou Rep Hospitals 2012	802
Table 5.62 Top 20 Anticancer Drugs by Sales in 34 Nanjing Rep Hospitals 2012	802
Table 5.63 Top 20 Anticancer Drugs by Sales in 32 Wuhan Rep Hospitals 2012	803
Table 5.64 Top 20 Anticancer Drugs by Sales in 18 Chengdu Rep Hospitals 2012	804
Table 5.65 Top 20 Anticancer Drugs by Sales in 34 Chongqing Rep Hospitals 2012...	804
Table 5.66 Mental Disorder Drug Sales by TCs in Chinese Rep Hospitals 2011	813
Table 5.67 Number of Chinese Retail Pharmacy Outlets 2009-2012	817
Table 5.68 Chinese Retail Pharmacy Market Quarterly Growth 2010-2013	818
Table 5.69 Growth of Chinese Urban Retail Pharmacy Markets: 2013 vs. 2012	819
Table 5.70 Chinese Retail Pharmacy Market Growth by Product Category.....	819
Table 5.71 Top 20 TCs of Chinese Retail Drug Sales 2011-2012.....	821
Table 5.72 Top 10 TCs of Chinese Retail Western Medicine Sales 2011-2012.....	821
Table 5.73 Top 10 TCs of Chinese Retail TCM Sales 2011-2012	822
Table 5.74 Top 10 Chemical TCs in Chinese Retail Pharmacy Market 2012-2013.....	822

Table 5.75 Top 10 TCM TCs in Chinese Retail Pharmacy Market 2012-2013	823
Table 5.76 Top 10 Health Product TCs in Chinese Retail Pharmacy Market 2012-2013	823
Table 5.77 Top 20 Drug Brands by Chinese Retail Pharmacy Sales MAT Q2/2013.....	824
Table 5.78 Top 10 Drug Brands by Retail Pharmacy Sales in North China 2012-13....	825
Table 5.79 Top 10 Drug Brands by Retail Pharmacy Sales in East China 2012-2013 ..	826
Table 5.80 Top 10 Drug Brands by Retail Pharmacy Sales in Central South China 2012-2013	826
Table 5.81 Top 10 Drug Brands by Retail Pharmacy Sales in West China 2012-2013 ..	827
Table 5.82 Top 10 Cold Drugs by Chinese Retail Sales in 2013	828
Table 5.83 Top 10 Antibiotics Drugs Shares by Chinese Retail Sales in 2013.....	828
Table 5.84 Top 10 Vitamin Products by Chinese Retail Sales in 2013.....	829
Table 5.85 Top 10 Gastrointestinal Drugs by Chinese Retail Sales in 2013	829
Table 5.86 Top 10 Cardio-/Cerebro-vascular Drugs by Chinese Retail Sales in 2013 ..	830
Table 5.87 Top 10 Cough Drugs by Chinese Retail Sales in 2013	830
Table 5.88 Top 10 Skin Disease Drugs by Chinese Retail Sales in 2013	831
Table 5.89 Top 10 Anti-hypertension Drugs by Chinese Retail Sales in 2013	831
Table 5.90 Top 10 Gynecological Drugs by Chinese Retail Sales in 2013	832
Table 5.91 Top 10 Throat Medicines by Chinese Retail Sales in 2013	832
Table 5.92 Top 20 Western Medicine Products of Chinese Retail Sales 2011-2012	833
Table 5.93 Top 20 Chinese Pharma Companies by Retail Pharmacy Sales in 2013	834
Table 5.94 Top 10 Companies by Chinese Retail Pharmacy Sales MAT Q2/2013	834
Table 5.95 Top 10 Players by Chinese Retail Pharmacy Sales 2012-2013.....	835
Table 5.96 Top 20 Supplier by Chinese Retail Drug Sales 2011-2012.....	835
Table 5.97 Sales Size of Chinese Online Pharmacies 2010-2013E.....	836
Table 5.98 Number of Chinese Online Pharmacies	836
Table 5.99 Structure of Chinese B2C Online Pharmacy Sales in 2012.....	837
Table 5.100 Chinese OTC Drug Market 2008-2013.....	840
Table 5.101 Chinese OTC Drug Market Growth Rates 2008-2012.....	840

Table 5.102 Composition of OTC Drug Sales in Retail Pharmacies in 2012	841
Table 5.103 Chinese Retail Pharmacy OTC Sales Growth by TCs in 2012	842
Table 5.104 Chinese Retail Drug Sales 2011-2013: OTC vs. Rx	842
Table 5.105 Composition of Medical Institution Drug Sales: OTC vs. Rx	843
Table 5.106 Top 20 Products (OTC Drugs+Health Foods) of Retail Pharmacies in 2012	843
Table 5.107 China's Top 20 OTC Drug Companies in 2013	844
Table 5.108 China's Top 5 OTC Chemical Drug Brands in 2013.....	845
Table 5.109 Top 10 Formulated TCMs by Chinese Hospital Sales (May 2013)	850
Table 5.110 Composition of Chinese Pharma Market 2012: TCMs vs. WMs.....	851
Table 5.111 Hospital Market Share of Formulated TCMs by TCs 2012.....	851
Table 5.112 Market Share of Formulated TCMs by Hospital Tier 2012.....	851
Table 5.113 Formulated TCMs under NRDL 2000 Ed. & 2009 Ed.....	852
Table 5.114 Share of Formulated TCMs in Total NRDL Reimbursement 2010.....	852
Table 5.115 Share of NEDL FTCMs in Overall Chinese FTCM Sales Value by TCs in 2012.....	852
Table 5.116 Changing Hospital TCM Drug Consumption Patterns Since 2006.....	853
Table 5.117 Chinese Retail Drug Sales 2011-2013: WMs vs. TCMs	854
Table 5.118 Composition of Medical Institution Drug Sales: TCMs vs. WMs	854
Table 5.119 Chinese Drug Market Size Projections by Major Segments 2013-2015	856
Table 5.120 Structure of Shanghai Hospital Drug Sales by Hospitals Tier in 2012	858
Table 5.121 Regional Hospital Drug Consumption Growth Trend 2009-2011.....	858
Table 5.122 Drug Consumptions in 263 Rep Hospitals of Six Chinese Cities 2008-2012	859
Table 5.123 Top Suppliers by Hospital Drug Sales Value in Six YRV Cities 2012.....	859
Table 5.124 Leading Suppliers by Drugs Sales Value in 119 Shanghai Rep Hospitals 2012	860
Table 5.125 Leading Suppliers by Drugs Sales in 26 Hangzhou Rep Hospitals 2012 ..	860
Table 5.126 Leading Suppliers by Drugs Sales in 32 Wuhan Rep Hospitals 2012.....	861

Table 5.127 Leading Suppliers by Drugs Sales Value in 34 Nanjing Rep Hospitals 2012	861
Table 5.128 Leading Suppliers by Drugs Sales in 34 Chongqing Rep Hospitals 2012.	862
Table 5.129 Leading Suppliers by Drugs Sales in 18 Chengdu Rep Hospitals 2012	862
Table 5.130 Tiered Composition of the Chinese Retail Pharmacy Sector in 2011(1) ...	864
Table 5.131 Tiered Composition of the Chinese Retail Pharmacy Sector in 2011(2) ...	864
Table 5.132 Tiered Composition of the Chinese Retail Pharmacy Sector in 2011(3) ...	864
Table 5.133 Regional Distribution of Chinese Retail Pharmacy Outlets 2012.....	866
Table 5.134 Regional Distribution of Chinese Retail Pharmacy Outlets H1/2013.....	866
Table 5.135 Chinese Retail OTC Drug Consumption Value by City Tier 2012	867
Table 5.136 Top 10 TCs by Share of Rx Value and Rx Number in Shanghai Rep CHCs in 2013.....	869
Table 5.137 Top 10 TC Subclasses by Rx Value Share and Growth in Shanghai CHCs in 2013.....	870
Table 5.138 Top 10 Drugs by Rx Value Share and Growth in Shanghai Rep CHCs in 2013	870
Table 5.139 Top 10 NEDL Products in Shanghai Rep CHCs in 2013.....	871
Table 5.140 Market Share of Imported Drugs in Ten Major Chinese Cities in 1995	872
Table 5.141 Hospital Market Shares of Local, JV and Imported Drugs 2006-2013.....	875
Table 5.142 Hospital Drug Market Shares in 263 Rep Hospitals of 6 YRV Cities 2009-2012	877
Table 5.143 Shares of Local & JV/Foreign Companies in Retail Drug Sales 2004-06.	878
Table 5.144 Shares of Domestic and MNCs in Retail Prescription Drug Sales by TCs 2012.....	880
Table 5.145 Shares of Innovative Drugs, Generics and TCMs in China 2012 (1)	881
Table 5.146 Shares of Innovative Drugs, Generics and TCMs in China 2012 (2)	882
Table 5.147 Top 10 MNC Companies by Hospital Drug Sales in 2013	882
Table 5.148 MNCs in Top 20 Chinese Pharma Cos by Retail Pharmacy Sales 2013 ...	883

LIST OF CHARTS

Chart 2.1 Overall Chinese Drug Market Size and Growth 2007-2013	136
Chart 2.2 Gross Output Value of Chinese Pharmaceutical Industry 2006 – 2013	143
Chart 2.3 Composition of Chinese Pharmaceutical Industry by Output Value in 2013.	143
Chart 2.4 Output Value of Six Chinese Pharma Sub-sectors in 2013	144
Chart 2.5 Core Business Revenues of Chinese Pharmaceutical Industry 2006 – 2013 .	144
Chart 2.6 Composition of Chinese Pharmaceutical Industry by Revenues in 2013	145
Chart 2.7 Revenues of Six Chinese Pharma Sub-sectors in 2013	145
Chart 2.8 Net Profit of Chinese Pharmaceutical Industry 2006 – 2013	146
Chart 2.9 Composition of Chinese Pharmaceutical Industry by Net Profits in 2013.....	146
Chart 2.10 Net Profit Growth of Six Chinese Pharma Sub-sectors in 2013	147
Chart 2.11 Sales Margin Trend of the Chinese Pharma Industry 1997-2013.....	147
Chart 2.12 Sales Margins of Six Chinese Pharma Sub-sectors 2011-2013.....	148
Chart 2.13 Gross Output Value of Chinese Biopharma Industry 2006-2013.....	157
Chart 2.14 Revenues of Chinese Biopharma Industry 2006-2013.....	158
Chart 2.15 Net Profit of Chinese Biopharma Industry 2006-2013	158
Chart 2.16 China’s Biopharmaceutical Drug Import Origin Countries in 2012	159
Chart 2.17 Chinese Pharmaceutical Distribution Industry Performance 2007-2013.....	165
Chart 2.18 Chinese Pharmaceutical Distributor Sales by Product Categories in 2013..	166
Chart 2.19 Chinese Retail Pharmacy Market Segmentation in 2013.....	166
Chart 2.20 Distribution of Pharma Industry Sales by Ownership in 2013.....	167
Chart 2.21 Distribution of Pharma Industry Profit by Ownership in 2013	167
Chart 2.22 Profit Margins of the Chinese Pharma Distribution Sector Since 2002.....	169
Chart 2.23 R&D Centers of RDPAC Members by Research Stage in China	187
Chart 2.24 R&D Centers of RDPAC Members by Function in China.....	187
Chart 2.25 Locations of R&D Centers of RDPAC Members in China.....	188
Chart 2.26 Chinese Market Access by New Drugs - 1 Year After Launch	189
Chart 2.27 Chinese Market Access by New Drugs - 2 Years after Launch.....	189

Chart 2.28 Share of Top 100 in Chinese Pharma Manufacturing Sector Sales 2006-2013	202
Chart 2.29 Number of Chinese Retail Pharmacy Chains 2006- 2013	208
Chart 2.30 Number of Chinese Retail Pharmacy Stores 2006-2013	208
Chart 2.31 Compulsory License Application Process.....	251
Chart 2.32 Application Procedures of APP	257
Chart 2.33 Flowchart – Revocation Procedures of APP	258
Chart 2.34 Re-examination Procedures of APP.....	259
Chart 2.35 Infringement Settlement Procedures of APP	260
Chart 2.36 Chinese Hospital Market Growth 2007-2013	304
Chart 2.37 Number of Chinese Retail Pharmacy Stores 2006-11/2013	311
Chart 2.38 Structure of Retail Pharmacy Outlets Since 2006.....	311
Chart 2.39 Number of Chinese Retail Pharmacy Chains Since 2006.....	312
Chart 2.40 Number of Outlets Owned by Chinese Retail Pharmacy Chains Since 2006	312
Chart 2.41 Number of Independent Chinese Retail Pharmacy Stores Since 2006	313
Chart 2.42 Growth of Chinese Retail Pharmacy Sales Since 2000	314
Chart 2.43 Shares of Retail Drug Sales Channels Since 2007.....	315
Chart 2.44 Drug Consumption by THCs and CHCs in China 2008-2013.....	322
Chart 2.45 Vaccine Sales in Representative Hospitals of 22 Chinese Cities	329
Chart 2.46 Prophylactic Vaccine Sales in Rep Hospitals of 22 Chinese Cities	329
Chart 2.47 Therapeutic Vaccine Sales in Rep Hospitals of 22 Chinese Cities	330
Chart 2.48 Rabies Vaccine Sales in Rep Hospitals of 22 Chinese Cities.....	330
Chart 2.49 Growth of Chinese OTC Drug Market 2009-2013	333
Chart 2.50 Chinese OTC Drug Market Size 2000-2011	336
Chart 2.51 Size of Chinese OTC Drug Sales Channels 2007-2011	336
Chart 2.52 Chinese Online Retail (B2C) Drug Sales 2011-2015E	349
Chart 2.53 Regulatory Filings by Chinese Companies in EU and U.S.....	357
Chart 2.54 US DMF Filings vs. US FDA Inspections in China	357

Chart 2.55 API Manufacturer Ratings: China vs. India vs. Italy	359
Chart 2.56 US DMF Filings: China vs. India vs. Italy.....	359
Chart 2.57 COS Filings: China vs. India vs. Italy.....	360
Chart 2.58 US FDA Inspections: China vs. India vs. Italy.....	360
Chart 2.59 Progression of Chinese API Manufacturer Ratings: 2005 vs. 2011	361
Chart 2.60 Chinese Foreign Trade of MHPs 2008-2013.....	369
Chart 2.61 Export Value of Medicines and Health Products in China Since 2001	372
Chart 2.62 Chinese API Group Manufacturer Ratings.....	376
Chart 2.63 Progression of Chinese API Group Manufacturer Ratings: 2005 vs. 2011 ..	377
Chart 2.64 Regulatory Filings by Chinese Groups	378
Chart 2.65 Regulated Market Activity Deals: API and Intermediates	378
Chart 2.66 Regulated Market Activity Deals: FDF & Development Agreements.....	379
Chart 2.67 Eight Chinese Groups Hold A Combined 28 ANDAs with Final FDA Approval	380
Chart 2.68 Follow-on Biologic Development among Chinese Groups	381
Chart 3.1 CFDA Accepted Drug Registration Applications in 2009-2013	387
Chart 3.2 Chemical Drug Registration Applications Accepted by the CFDA in 2012-2013	388
Chart 3.3 Reported Adverse Drug Reaction Events by Type in 2013.....	391
Chart 3.4 Reported Adverse Drug Reaction Events by Age in 2013	391
Chart 3.5 Senior Population’s Share Of ADR Events 2009-2013.....	392
Chart 3.6 Reported Adverse Drug Reaction Events by Source in 2013.....	392
Chart 3.7 Reported Adverse Drug Reaction Events by Drug Dosage Forms in 2013 ...	393
Chart 3.8 Administrative Structure of Food and Drug Regulation in China.....	421
Chart 3.9 CFDA Organizational Chart.....	422
Chart 3.10 Application and Approval Procedures for Clinical Trials	485
Chart 3.11 Application and Approval Procedure for Imported Drugs (1).....	489
Chart 3.12 Application and Approval Procedure for Imported Drugs (2).....	489
Chart 3.13 Supplemental Application and Approval Procedure for Imported Drugs (1)	

.....	490
Chart 3.14 Supplemental Application and Approval Procedure for Imported Drugs (2)	491
Chart 4.1 Healthcare Spending by Funding Source 1980-2013(CNY bln)	657
Chart 5.1 Growth of Healthcare Expenditures in China Since 2000	726
Chart 5.2 Growth of Per Capita Healthcare Expenditures in China Since 1990	727
Chart 5.3 Composition of Healthcare Expenditures in China Since 2000	728
Chart 5.4 BMI by Total Adults in Each Geography	760
Chart 5.5 Pre-Diabetes and Type 2 Diabetes in Each Geography	761
Chart 5.6 Attitudes among Type 2 Diabetes Patients (% agree/strongly agree)	762
Chart 5.7 Oncology Drug Consumption by Rep Hospitals in 16 Chinese Cities 2006-2012	798
Chart 5.8 Lung Cancer Drug Consumption by Rep Hospitals in 16 Chinese Cities 2006-2012	799
Chart 5.9 Consumption of Carboplatin/Lobaplatin/Nedaplatin Drugs by Rep Hospitals in 16 Cities 2006-2012	799
Chart 5.10 Changing Mental Disorder Hospital Drug Consumption 2005-2011	814
Chart 5.11 Chinese Retail Pharmacy Market Segmentation Since 2004	820
Chart 5.12 B2C Pharmacy Market Share by Channels in 2013	837
Chart 5.13 B2C Pharmacy Market Share by Product Categories in 2013	838
Chart 5.14 B2C Online Pharmacy Market Share by Genders in 2013	839
Chart 5.15 Top 10 Therapeutic Categories by OTC Drug Sales in China 2013	841
Chart 5.16 Chinese Hospital Drug Consumption by City Tier 2008-2012	857
Chart 5.17 Chinese Hospital Drug Sales Growth by City Tier 2009-2012	857
Chart 5.18 Regional Retail Pharmacy Markets in China 2011	865
Chart 5.19 Provincial Retail Pharmacy Markets in China 2011	865
Chart 5.20 Chinese OTC Drug Consumption Value by City Tier and Sales Channel 2012	867
Chart 5.21 Chinese Retail OTC Drug Consumption Value by Cities 2012	868
Chart 5.22 Rx Drug Growth in Various Levels of Shanghai Rep Medical Facilities 2013	

.....	869
Chart 5.23 China Hospital Market by TC Sales Value in 2013: Domestic vs. MNCs	.874
Chart 5.24 China Hospital Drug Market by TC Sales Volume in 2013: Domestic vs. MNCs874
Chart 5.25 Chinese Hospital Drug Consumption by City Tier and Supplier Origin 2012875
Chart 5.26 Hospital Drug Sales Growth Contribution by City Tier and Supplier Origin 2012876
Chart 5.27 Structure of Chinese Retail Pharmacy Market in 2013: Domestic vs. MNCs879
Chart 5.28 Shares of MNCs and Domestic in Chinese Prescription Drug Sales 2012	.880

This Page is Left Blank Intentionally

TABLE OF ABBREVIATIONS

ADR – Adverse Drug Reaction	MOH – Ministry of Health
API – Active Pharmaceutical Ingredients	MoHRSS – Ministry of Human Resources and Social Security
APP – Administrative Protection of Pharmaceuticals	NHFPC – National Health and Family Planning Commission
AmCham – American Chamber of Commerce	MNC – Multinational pharmaceutical companies (<i>in the context of this guide</i>)
CAGR (Compound Annual Growth Rate)	MR – Medical Representative
CCCIEMHP – China Chamber of	NBS – National Bureau of Statistics
CFDA – China Food and Drug Administration (formerly State Food and Drug Administration or CFDA)	NCGHSR - National Coordination Group for Healthcare System Reform
Commerce for Import & Export of Medicines and Health Products	NDRC – National Development and Reform Commission
CNCM – China National Corporation of Medicines	NHFPC – National Health and Family Planning Commission
CAPC – China Association of Pharmaceutical Commerce	OECD – Organization for Economic Co-operation and Development
CNY – Chinese Yuan	OTC – Over the Counter
CRO – Contract Research Organization	QA – Quality Assurance
DRGs – Diagnosis Related Groups	QC – Quality Control
ED – Erectile Dysfunction	PRC –People’s Republic of China
FDI – Foreign Direct Investment	R&D – Research and Development
FIEs – Foreign Invested Enterprises	RDPAC - R&D-based Pharmaceutical Association Committee in China
GCP – Good Clinical Practices	SATCM – State Administration of Traditional Chinese Medicine
GDP – Gross Domestic Products	SDA – State Drug Administration
GLP – Good Laboratory Practices	CFDA – State Food and Drug Administration of China (now China Food and Drug Administration or CFDA)
GMP – Good Manufacturing Practices	SIPO – State Intellectual Property Office
GSP – Good Supply Practices	SMEI – Southern Medicine Economic Institute under the CFDA
IFPMA – International Federation of Pharmaceutical Manufacturer Associations	SOE – State Owed Enterprise
JV – Joint Venture	SPAC – State Pharmaceutical Administration of China
M&A – Merger and Acquisition	STD – Sexually Transmitted Disease
MIIT – Ministry of Industry and Information Technology	TC – Therapeutic Class
MOFCOM or MOC – Ministry of Commerce	
MOF – Ministry of Finance	

TCM – Traditional Chinese Medicine

WHO – World Health Organization

USTR – US Trade Representative

WTO – World Trade Organization

VAT – Value Added Tax

VC – Venture Capital

WM – Western medicine

EXECUTIVE SUMMARY

James J. Shen

China's full-year GDP growth in 2013 came in at 7.7%, steady from 2012 and just slightly above market expectations for a 7.6% expansion and the official target of 7.5%. Well, official figures can say whatever the Chinese authorities want them to say, but there is widespread agreement among observers that the country's economy is suffering a longer-term slowdown.

Beijing has been saying it will accept slower growth as it tries to reshape the economy toward sustainable growth that is based on consumer demand, after three decades of breakneck expansion driven by exports and credit. The history of transitions from export-led models doesn't make for pretty reading. These transitions for Japan in 1973 and South Korea in 1991 led to sharp slowdowns in economic growth.

Meanwhile, a few analysts warned about the possibility of China's economy heading for a crash in 2014. Such bearish predictions are often dismissed casually, with the vast majority of economists and policymakers being sanguine about the country's economic prospects, pointing to still healthy data and confidence in recently-announced structural reforms to steer China in the right direction.

Continued slowdown of pharmaceutical sector growth last year

As predicted, the *Year of Black Water Snake (2013)* brought lots of unexpected changes, instability, and changeability to the sector, while the previous *Year of the Water Dragon (2012)* was generally more auspicious by comparison despite some anticipated turbulences. It is well known that the Chinese pharmaceutical industry, especially research-based MNCs, were overwhelmed for the most part of last year by selective government crackdown on unethical marketing practices and intensified pressure on prices of originator and premium branded drug products.

By large the Chinese pharmaceutical sector still saw double-digit growth in 2013 despite a host of challenges stemmed from slowing Chinese economy, regulatory shakeups, cost containment measures and price cuts, as well as healthcare reform turbulences. Revenue and profit growth last year inherited the down trend from 2012, although their rates were still considered robust compared with the global pharmaceutical industry and most of other Chinese industries.

Overall pharma industry and subsector performance

Total output value for the Chinese pharmaceutical industry is expected by the Southern Medicine Economic Institute (SMEI) under the CFDA to grow 20.45% for 2013, reaching a total of CNY 2,270 billion (US\$372.6 billion). The predicted growth is in par with that of 2012, although official data shows that the industry's revenue growth slowed again in the second and third quarters of 2013, after rebounding marginally in the previous three quarters.

The Chinese pharmaceutical market at the retail level is estimated to reach a total of CNY 1,145.8 billion, up 17.5% year on year, according to Sinohealth Pharmaceutical Consulting Group's *Bluebook for Analysis of Six Chinese Drug Consumption Terminal Markets (2012-2013)*.

Separately, Business Monitor's newly-published *China Pharmaceuticals and Healthcare Report Q1 2014* also predicts that the Chinese pharmaceutical market size would grow 17.5% in local currency and 19.6% in US dollar terms. The company also expects the Chinese healthcare expenditures to grow from CNY 2,845.6 billion (US\$451.1 billion) in 2012 to CNY 3281.6 billion (US\$527.6 billion) in 2013, up 15.3% in local currency terms and 17.0% in US dollar terms.

IMS suggests that the overall Chinese pharmaceutical market rose 14.5% in 2013 and it replaced Japan as the second largest pharmaceutical market in the world, two years earlier than estimated. The Chinese hospital drug market also grew 13.4% in the same year to CNY 550.7 billion at hospital purchase prices. The market continued a growth downtrend due to restrictions on antibiotic usage, price cut and cost containment in major cities.

Sinohealth also projects the Chinese retail pharmacy market to be CNY 198.5 billion in 2013, up 10.4%. On the other hand, Data from *IMS PharmaTrend*, a retail pharmacy audit covering 288 prefecture level cities, indicates that the growth of Chinese retail pharmacy market rose to 10% in 2013 (from 6.4% in 2012), reaching a total size of CNY 101.7 billion.

Specifically on the Chinese OTC drug market, Nicholas estimates the Chinese OTC drug market (OTC drug sales in all retail channels, prescription sales of OTC-registered brands plus packaged herbal medicines (including branded TCMs) to be US\$18,030 million at manufacturer-suggested price (MSP) in 2013, up 6.8% year on year. The growth last year resulted from more OTCs being prescribed via hospitals and more branded OTCs being consumed by the rural population.

2013 added more than 60 B2C retail drug sales approvals and the size of Chinese online pharmacy market should have reached CNY 4.0 to 4.5 billion in 2013, according to ZHANG Yong, Secretary General of the Chinese Online Pharmacy Society (COPS). Drug sales is estimated by Zhang to account for only 45% of Chinese online pharmacy sales and the rest 55% are made up by healthcare supplements, contraceptive products, contact lenses and home medical appliances.

Last, but not the least, the Chinese import and export trade of medicines and health products grew 10.27% in 2013 to US\$89,693 million in 2013, according to the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCIEMHP). Among the total, export increased 6.84% to US\$51,180 million while import rose 15.17% to US\$38,513 million. Growth of both import and export slowed in 2013 and China's surplus of such trade narrowed 12% in the year to US\$12,666 million. While the country's total foreign trade in the pharmaceutical industry increased, a significant portion of the uptick was due to higher domestic demand for premium quality drugs from abroad, which led to increased imports.

Government reorganization reinforces drug regulatory regime as NDRC struggles with drug price reform

In early 2013, the new Chinese leadership engineered a major reorganization of China's healthcare regulatory regime to streamline jurisdictions and processes and to improve efficiency and strengthen regulation.

Developments were across many different areas of drug regulation last year with the newly-created CFDA remaining to be preoccupied with promotion of drug quality and registration/evaluation efficiency.

On the front of drug pricing, NDRC, which was minimally affected by the government reorganization, is still overwhelmed by stakeholder disputes and has failed to make up its mind about the reform direction for another year.

Central government reorganization

Reorganization of central government agencies under the State Council began in late March with the establishment of a few new agencies. In healthcare, the National Health and Family Planning Commission (NHFPC) was officially inaugurated on March 18 to replace the Ministry of Health (MOH) and the National Population and Family Planning Commission (NPFPC). Days later, the China Food and Drug Administration (CFDA) was officially inaugurated merging the former CFDA and relevant food and drug regulatory functions under a number of other central government agencies. In order to cope with its sharply expanded jurisdictions, CFDA sought to simplify, consolidate and decentralize some of its responsibilities in phases over a few years.

While reinforced standing of CFDA in drug regulation has been rather productive, resulting in improved legal framework, higher efficiency and better enforcements last year, outcomes from boosted role of the NHFPC in healthcare reform has been rather mixed, given the agency's vested interest in and official responsibilities for the state-owned hospital sector.

Drug registration and review

CFDA, the predecessor of CFDA, kicked off last year with a new policy, "*Opinions on Deepening Drug Evaluation and Approval Reform and Further Encouraging Drug Innovation*" in February 2013. The document seeks to improve the Chinese drug registration regime, enhance the efficiency and standards of drug evaluation, and accelerate review and approval of selected innovative and generic drugs.

It also issued the *Plan for Bioequivalence Study of Generic Drugs* which mandates phased compulsory bioequivalence studies for all generic chemical drugs approved before October 1, 2007 and preliminary development of the list for reference originator drugs. Through the process, the agency hopes to raise overall level of generic drugs in China to or near "advanced international standards". This requirement would begin with selected essential drugs in 2013 and then be expanded to other generic drugs between 2015 and 2020.

Drug quality and safety

CFDA pushed hard in 2013 on implementation of the new 2010 GMP and 2013 GSP, which went into effect on June 1, 2013 and requires phased full implementation before the end of 2015. As of the beginning of this year, the 2010 edition of GMP was fully implemented for sterile drug products.

In a bid to improve clinical research quality in China, the Center for Drug Evaluation (CDE) under the CFDA announced on September 17, 2013 the completion of its Drug Clinical Trial Registration and Information Public Platform (www.chinadrugtrials.org.cn). A few days earlier, the agency issued its No.28 Announcement which requires all its approved clinical trials in China to register and publish information on the platform. Similarly, the agency released in late 2013 a series of rules and guidelines to improve quality control of vaccine clinical trials and production.

Drug pricing reform and antitrust enforcement

Instead of earlier proposals to focus regulatory efforts on drug sales margins in the distribution process, NDRC has reportedly turned to three new options for drug pricing reform since mid-2013: 1) abandoning the approach to set maximum retail prices of drugs which is now viewed by some experts as an outdated regulatory model and ineffective against irregular drug sales margins in the distribution process; 2) trials of uniform drug reimbursement guidance price system under which NDRC will put emphasis on uniform reimbursement prices of the BMI system with excess costs above such prices to be picked up by patients, thus encouraging price competition among pharmaceutical companies; and 3) the issue lingers on as to if China should maintain the existing separate pricing policy of off-patent originator drugs.

The agency's latest move in December 2013, the *Notice on Improving Price Regulation of Low-cost Drugs*, reflects to some extent its new ideas about drug regulation. The document defines low-cost drugs as "those drug products priced relatively lower among similar drugs for a given indicated disease". Government-set maximum retail prices are withdrawn for such drug products and, instead, daily average consumption limits are set. Below the limits, manufacturers are free to set their prices which should be filed with provincial level price authorities.

In a separate development, the NDRC indicated in late 2013 that it would continue to crack down on excessively high prices in six industries (including the pharmaceutical industry) through enforcement of anti-price monopoly laws and regulations.

Slow and superficial progress seen for healthcare reform in 2013

Plagued by structural flaws, inadequate government financing as well as conflict of interests among different agencies and stakeholders, China's ongoing healthcare reform remained to be bottlenecked in 2013 despite some superficial progresses.

It is understandable that the *Third Plenum of the 18th Party Congress* had little to say about the ongoing healthcare reform other than calling to deepen it. Indeed, all top-level reform plans over healthcare seem to be well-developed and it is the actual funding and execution at the local levels that have been holding things up.

The central government, nonetheless, claimed victory as usual with release of various

official data to show progress as perceived by them on different reform fronts as well as their plans forward. Let's take a look at these as follows.

National policy environment and central government funding

The State Council issued a new policy, *Certain Opinions for Promoting Development of Healthcare Services*, in October 2013. The document sets a target of boosting the gross value of China's healthcare service sector to over CNY 8 trillion (US\$1.31 trillion) by 2020. Central government subsequently allocated CNY 2.22 billion (US\$358.3 million) to the healthcare service sector to improve well-being and shore up growth as provided the new policy. The new policy is expected to create a more favorable environment for private capital in the sector. It also demands relevant authorities to take advantage of TCM in disease prevention and healthcare.

Earlier, the NHFPC and the Ministry of Finance (MOF) issued a joint notice calling for the elevation of per capita funding for the New Rural Cooperative Medical Scheme (NRCMS) to CNY 340 in 2013. This meant the total NRCMS funding would reach a total of over CNY 280 billion, an expansion of CNY 41.6 billion compared with 2012.

BMI and major medical coverage

A document recently released by the Ministry of Finance, *Explanatory Notes for Final Accounts of National Social Security Funds in 2012*, shows that the urban employee basic medical insurance (BMI) and the urban resident BMI programs had annual surpluses of CNY 118.3 billion and CNY 26.8 billion respectively in 2012. By the end of 2012, both programs had accumulated surpluses of CNY 668.2 billion and CNY 161.1 billion respectively, totaling CNY 829.3 billion. With such huge annual and accumulated surpluses, it seems unfounded for the Chinese government to continue preoccupying itself with healthcare cost containment. But some analysts argue that, while the BMI programs show huge surpluses nationally in the past few years, the health of local BMI funds deviate sharply across the country.

Never mind the surpluses, Ministry of Human Resources and Social Security (MOHRSS) said in late 2013 it would deepen reform of BMI payment schemes, fully implement overall BMI spending caps, conduct trials of real time BMI surveillance systems, strengthen regulation of medical services, investigate and improve provisions for out-of-territory BMI reimbursement, and push forward trials of urban and rural resident major medical insurance.

As to major medical insurance programs, MOHRSS reported in October 2013 that a total of 23 provincial level governments had introduced implementation plans for major medical insurance programs in their jurisdictions and 120 trial site cities had been selected.

Public hospital reform

In late 2013, the Chinese government reported completion of its preliminary assessment of the experiment for phasing out the 15% drug sales margin in county level public hospitals. Public hospitals in 311 national trial site counties have all removed the margin and the measure has also been fully implemented in county-level public hospitals

province-wide in Shaanxi, Anhui, Zhejiang and Qinghai provinces.

The county level public hospital reform is therefore deemed by the State Council's Healthcare Reform Office to be "successful at this stage" and it has subsequently announced its plan to initiate the second round experiment of county level public hospital reform at the end of this year and full public hospital reform implementation nationwide in 2015.

Essential drug system (EDS)

The MOH issued the 2012 Edition of *National Essential Drug List* (NEDL) which went into effect on May 1, 2013. As previously speculated, the new list contains a total of 520 drugs including 317 chemical drugs and biological products as well as 203 formulated traditional Chinese medicines. What came as a surprise is that the accompanying official notice is very low key with how the new NEDL should be implemented locally. Such an approach may weaken the role of this new NEDL and lead to substantial regional variances for future implementation.

To support implementation of the 2012 NEDL, the government plans to introduce a range of complementary policies to support its implementation. The NHFPC sought industry comments in late 2013 on a proposed new policy, *Rules for Expanding Essential Drug Consumption*, which proposes to set a minimal 40% ratio for essential drug consumption in level II and III public hospitals.

In the meantime, the central government has ordered provincial level governments to conduct thorough reviews and strictly control the number of essential drug supplements to the new 2012 NEDL repeatedly, but a string of local governments, including Jiangxi, Shanxi, Guangdong and Qinghai provinces and Chongqing, have ignored central government mandates and expanded their provincial level EDLs substantially, while other local governments such as Hunan, Jiangxi, Shaanxi and Jilin provinces as well as Shanghai have pledged not to escalate their local EDLs.

National Drug Reimbursement List (NDRL)

There are growing gossips among industry insiders that the existing NDRL will be reviewed with a new list likely to be released within 2014. Earlier rumors pointed to start of the review process in November 2013 with a new NDRL released in mid-year. It is suggested that the government will try to maintain the same number of drug products in the NDRL. There has been no response to such speculations so far.

Nonetheless, industry analysts expect the number of drug products in the new NDRL to increase and they suggest the matter to be clouded by many uncertainties and therefore it is even optimistic to expect release of the new NDRL before the end of 2014.

Factors affecting the revision of NDRL include implementation progress and results of the 2012 NEDL and provincial level essential drug supplemental lists, major medical insurance programs and low-cost drug lists at the local government levels. These reform measures need to be integrated with the new NDRL. In addition, uncertainties surrounding the central government-proposed integration of China's three BMI programs, namely the urban employee BMI program, urban resident BMI program and NRCMS, are expected to

affect the NDRL revision progress significantly.

Centralized hospital drug purchase tenders

2014 is a year when most provinces are expected to execute their respective centralized drug purchase tenders. As such, the NHFPC revealed its policy outlook for tenders in November 2013 including: 1) policy documents setting out specific ratios for essential drug consumption by all levels of hospitals are likely to be issued in December this year; 2) price cut of non-essential drugs will be in the spotlight again next year; and 3) prices of off-patent originator drugs may be targeted for further reduction.

Cost reduction of non-essential drugs will be moving to the top of government agenda in 2014, suggested relevant government officials at a NHFPC event in late 2013. They hope to achieve this objective through further price cuts and modification of tender purchase policies, such as eliminating or reducing policy preference of originator drugs at tenders.

Fighting corruptions in healthcare

In its latest attempt to crackdown on widespread corruption in the Chinese healthcare sector, the NHFPC unleashed two new measures before the end of 2013. The first is the *Notice on "Nine Prohibitions" to Strengthen Healthcare Industry Compliance* which sets out comprehensive anti-corruption requirements to be observed by hospitals and physicians, and expressly prohibits nine types of non-compliant activities, while the second is the amended *Provisions for Establishing Bad Records of Commercial Briberies in Medical & Pharmaceutical Sales & Purchase* with effect on March 1, 2014, updating a "blacklist system" on pharmaceutical and medical device companies that are convicted of commercial bribery.

MNCs remain committed to China despite wrath of government crackdown and strengthened domestic competition

The tumultuous Chinese healthcare marketplace took a breath in the first half of 2013 before the new Chinese leadership began to show their prowess with new directions, policies and actions.

As such, the year of 2013 had a good start with renewed optimism following release of slower but still inspiring 2012 industry data, impressive annual growth reported by both domestic and MNC players, as well as proactive investment plans, pledges of ambitious expansion, and an uptick of business activities such as joint ventures, strategic alliances and licensing.

But the business climate for the pharmaceutical industry in China, took a sudden turn in late May when dramatic police investigation of GSK corruption scandal began with arrests and later public parades on TV of the company's senior executives, consultants and related travel agents.

Chinese government targets MNCs for selective law enforcement

Government crackdown on corruption in drug sales dominated the pharmaceutical business landscape for the 2nd half of 2013 and the first half of 2014, and substantially affected performance of the Chinese pharmaceutical industry, especially MNCs. Initial

government actions obviously targeted at MNCs with the hidden agenda of pressuring them into cutting premium drug costs.

From start of the GSK investigation, the Chinese media has been filled with negative news on MNC drug giants. A growing list of multinational companies, including UCB, AstraZeneca, Sanofi, Novartis (including its Alcon division), Novo Nordisk, Baxter and Eli Lilly, reported visits and investigations by various government agencies. Some of these cases seemed planned, while many others were triggered by copycat whistleblowers or media reports.

Regardless of what the initial targets of the Chinese government were, the shock wave spilled over to domestic players as of last September as corruption allegations by insiders become almost viral. Leading Chinese companies, starting with Gan & Lee Pharma and followed by Chiatai Tianqing, EddingPharm, Shanghai Pharmaceutical Group and SinoPharm Group, were drawn into the mud pool of corruption in drug sales.

Pressures from the government have cowed a number of MNCs, in particular GSK, into pledging to lower costs of their products at least superficially to win government lenience. In reality, none of these companies have come out with concrete and voluntary price cuts and the pressure on them to do so is subsiding.

MNCs also began to fight back the Chinese government hostility through their home governments and trade associations. Examples include British Prime Minister speaking up for GSK, criticisms of EU Chamber of Commerce in China on unfair treatment of foreign companies, call by EUPIA for better transparency of corruption probes, and release of a position papers by RDPAC and PhRMA to urge drug quality improvement. At the same time, RDPAC also tried to mend fences for MNCs by letting go the membership of GSK for now and entering an agreement to implement "*Codes of Ethics for Chinese Pharmaceutical Enterprises*", which is originated from APEC's Mexico City Principles, with eight other Chinese pharmaceutical industry associations.

On the part of GSK, the company cleverly aired about its frustration through leaking internal talks of abandoning China and then denied it publicly. It also followed up with cooperative attitudes with the Chinese investigation, pledges to stay put in China and concrete steps to reform its sales practices. Most recently, Actavis made a high profile announcement to exit China because of the country's "unfriendly business climate".

These moves have softened and pressured the Chinese authorities at the same time. Through various channel, the government conveyed its continued friendliness and support to foreign investment and pharma MNCs. Apparently this may have contributed to the slow progress of the ongoing investigations and probably even indecisions as to how these cases should be wrapped up.

It is notable the NHFPC released two new anti-corruption measures in December 2013, indicating its commitment to combat corruption in healthcare. Earlier, the NHFPC and a number of other central government agencies also pledged to bolden the fight against commercial briberies in drug sales for three years beginning 2013.

Before MNCs found any relief from seemingly subdued government actions, new worries

arose from the official GSK investigation that lasted ten long months which has now culminated in the Chinese police charging the former China head of GlaxoSmithKline with bribery. Officials from the Ministry of Public Security (MPS) alleged that the executive, U.K. national Mark Reilly, ordered his sales team and other employees to bribe hospital doctors, medical institutions and other parties on "a large scale" to boost drug sales in China.

Rather than laying all the blame on individual GSK executives, the the official mouthpiece Xinhua pointed to corporate GSK for premeditation and systematic execution of various bribery practices as well as deliberate cover-ups, indicating the government's intention to hold the company responsible.

What came as a surprise to many, Xinhua centered substantial firepower on GSK's extraordinary profits in China and accused the company of moving profits overseas through transfer pricing and re-packing arrangements. By keeping huge profits off-shore, GSK was able to finance large scale commercial bribery activities in China, Xinhua alleges.

Besides, in the aftermath of GSK scandal, MNCs were also alerted by what's taken place in Hangzhou, where Roche's offices were raided by local industry and commerce officials. In addition, a number of other MNC companies including Eli Lilly, AstraZeneca and Novo Nordisk are reportedly handpicked by the local health department as primal targets for corruption investigations.

Confidence cracked but not shaken, MNCs remain committed to China

Big Pharma thought China had the cure for two conditions the global pharma industry had long endured: anemic sales growth in developed markets and revenue erosion because of competition from generics. Yet after a few boom years, the China effect has started to fade as the country's economic began to slow and cost containment took over the center of healthcare reform in the last couple of years. In addition, U.S. and European pharma companies face a number of hurdles in their quest for greater access and faster growth in China where they are facing more intense competition from domestic players.

China is also becoming a bigger headache, McKinsey said. The business models that presented drug makers with solid growth in China are now under pressure. The risks of operating in China, such as the anti-bribery investigation and volatility caused by price cuts and tender timings, as well as protectionism, are now on the rise.

But MNCs seem ready to stay committed at least for now with its original plans of investments, business expansion and strategic alliances in China. Business activities of foreign companies only dampened shortly in the third quarter of last year and they gradually resumed towards the end of last year.

Last year, the name of China investment game for MNCs was R&D and manufacturing capacity expansion in the country to meet rising local and international demands. Many of them, including Pfizer, J&J, Boehringer Ingelheim, AstraZeneca, MSD, Merck Serono, Eli Lilly, Sanofi and GSK, proceeded with new projects and made major business maneuvers in the country.

There are no easy solutions for MNC players in China. Companies will need to boost compliance structures, reform business models, refocus China strategies, form more R&D and business partnerships with local companies, target diseases prevalent to China, leverage China's R&D and manufacturing capabilities globally, and integrate commercial investment plans with government objectives.

Improved performance of domestic drug companies

As MNCs were grilled by the government over compliance and price reduction, Chinese companies remained mostly intact last year and were in high spirits for business expansion. Many of them, especially leading domestic players, benefited from the fall of pharma giants like GSK.

By the end of 2013, 55 publicly-listed Chinese drug companies issued guidance for their 2013 performance. 42 or 76% of them predicted better results for the year, while only eight or 15% anticipated falling performance and three or 5% foresaw losses. Six companies expected more than 100% and 23 companies forecasted between 30% and 100% net earnings growth. By comparison, only 66 or 62% of the 107 listed Chinese pharmaceutical companies expected their profits to grow in the first half of last year before the GSK scandal.

Other than picking up lost grounds of MNCs, industry observers suggest that these listed companies with improving performance last year benefited significantly from earlier R&D investments into new and specialty drugs. It is hoped that downstream integration of hospital business by domestic companies would become yet another growth driver for them.

In the meantime, leading Chinese companies continued to push forward their international business expansion plans with substantial investments into regulatory compliance. By the end of July 2013, Chinese pharmaceutical companies had submitted a total of 1,532 DMF files to the USFDA and gained 463 COS certifications from EDQM, according to a recent article of *China Pharmaceutical News*. In addition, 37 Chinese finished drug producers received GMP certifications from regulatory authorities of EU, U.S. and Japan, and five were granted GMP certifications from the WHO.

Chinese players are taking more aggressive paths to expand their international business in recent years. Such endeavors include acquisitions of foreign companies, joint ventures with local companies, setting up foreign subsidiaries and research units, as well as licensing and co-development deals.

Cross-border licensing and R&D partnerships remained a hotspot in 2013

The Deals Monitor of *Pharma China* recorded a total of 48 events in the last quarter and 145 events in 2013. The leading categories of events last year were licensing deals (38) and M&A deals (38), followed by contract research/collaborative R&D (26) and joint venture/strategic alliance agreements (23).

Representing 92% all recorded licensing events last year, the number of Sino-foreign/foreign-foreign licensing deals surged 17% to 35 in 2013 compared with 30 in 2012 and only 22 in 2011.

There were also a total of 26 contract research/collaborative R&D deals recorded last year, down slightly from 29 such transactions in 2012. Among all such deals, 24 Sino-foreign contract research and collaborative R&D deals were recorded in 2013.

Chinese companies dominated heated M&A space

Domestic Chinese companies stayed on as the driving force behind the heated pharmaceutical M&A landscape in 2013. Leading state-owned conglomerates such as SinoPharm, China Resources and Shanghai Pharmaceutical continued to be active players of M&As. China and Hong Kong-listed drug companies as well as smaller players seeking IPOs also bought hard to expand business, diversify or improve product pipelines, while many overseas-listed players lost steam for M&As as they labored to exit the unfriendly foreign stock markets.

The number of major M&A deals recorded by *Pharma China* in 2013 (37) was roughly on par with 2012 (38) and 2011 (36), while the number of M&A agreements between Chinese and foreign companies last year (14) was down considerably from such deals in 2012 (18). Deals among domestic companies (23) accounted for 61% of all recorded M&A events last year.

On the other hand, there is a sustaining trend that Sino-foreign joint ventures are back in favor again in the pharmaceutical industry in the past couple of years.

Old IP issues remained as China undertook drastic IP and antitrust enforcements

A wide range of Chinese policies and practices in 2013 continued to generate significant concerns among foreign companies operating in China. Major issues included China's export restraints, investment restrictions, serious problems with IP rights enforcement, indigenous innovation policies, technology transfer initiatives, government subsidization, inappropriate use of trade remedy laws, and China's slow movement toward accession to the WTO Government Procurement Agreement, according to USTR's *2013 Report to Congress on China's Compliance with WTO*.

A range of developments and concerns are highlighted by the report specifically in the pharmaceuticals sector:

- ☞ *Pharmaceutical patents* - Of particular concern is China's State Intellectual Property Office (SIPO)'s interpretation of Article 26.3 and related provisions of China's Patent Law, which govern information disclosure requirements for pharmaceutical patent applications. As a result, pharmaceutical patent applications granted by U.S. and other leading patenting authorities are denied only in China. In addition, patents granted prior to the adoption of the more restrictive standards have been vulnerable to invalidation challenges in China based on the retroactive application of those standards.
- ☞ *Data exclusivity* – Foreign companies continues to be concerned about the extent to which China provides effective protection against unfair commercial use of, and unauthorized disclosure of, undisclosed test or other data generated to obtain marketing approval for pharmaceutical products. However, Chinese law does not

include an appropriate definition of the term "new chemical entity" for purposes of identifying new pharmaceutical products entitled to protection;

- ☞ *Regulation of bulk substances for APIs* – China is urged to adopt comprehensive reforms to ensure that all Chinese producers of bulk chemical and biological substances capable of being used as APIs for medicinal products be subject to CFDA's registration requirements and operate in compliance with GMP;
- ☞ China committed to allow foreign suppliers to distribute pharmaceuticals by December 11, 2004. Despite overall progress in this area, many restrictions affecting the pharmaceuticals sector continue to make it difficult for foreign pharmaceutical companies to realize the full benefits of China's commitments;
- ☞ *Price control* - In its WTO accession agreement, China agreed that it would not use price controls to restrict the level of imports of goods or services. China agreed that it would try to reduce the number of products and services on this list. In 2013, China continued to maintain price controls on several products and services including pharmaceuticals; and
- ☞ *Counterfeit Drugs* - Despite repeated anti-piracy campaigns in China and an increasing number of civil IPR cases in Chinese courts, overall piracy and counterfeiting levels in China remained unacceptably high in 2012. IPR infringement continued to affect products, brands and technologies from a wide range of industries including, among many others, pharmaceuticals.

In the fields of IP and antimonopoly law enforcement, 2013 saw two drastic actions by China intellectual property enforcement which are likely to have far reaching impacts and provide hints on future directions for such issues.

First and foremost, the SIPO's Patent Reexamination Board has declared the entire patent of Gilead Sciences's HIV/AIDS and hepatitis B drug Viread (tenofovir) invalid, after a challenge brought by a local Chinese firm Aurisco, which pointed to deficiencies in the drug's patent on novelty grounds.

SIPO announced a change to China's IP laws in 2012 permitting compulsory licensing, when sources indicated Viread as one of the government's targets. Gilead Sciences reportedly responded to the threat by offering substantial donations of Viread if purchasing levels were maintained, but this evidently was not enough. Rather than demanding a compulsory license for Viread, China chose to revoke Gilead's patent on the drug altogether.

In a separate development, A Shanghai court ordered two Chinese Johnson & Johnson subsidiaries to pay a pharmaceutical distributor CNY 530,000 (US\$85,800) in compensation for monopolistic pricing practices in August 2013.

The contract signed between Rainbow Medical and the Johnson & Johnson subsidiaries was a typical vertical monopoly agreement, said HUANG Yong, a consultant for the country's anti-monopoly committee and a professor at the University of International Business and Economics.

"China has begun to refer to the legal practices of the United States and the European Union and punish vertical monopoly practices," said Huang. "This will protect price competition and not hinder commercial choices of enterprises."

2013 also saw stream of antitrust investigations by Chinese regulators which sought to toughen enforcement of the country's anti-monopoly law enacted in 2008. In particular, authorities are paying attention to whether manufacturers are forcing retailers to set minimum prices for products.

Other IP developments include introduction of the third amendment to the trademark law which will come into force on May 1, 2014. The amended trademark law is praised by many experts to be a significant improvement on the past version of the trademark law.

Guarded outlook for 2013 with lots of uncertainties ahead

Even with the new Chinese leadership and the communist party recently reinstating its pledge to continue broad economic and healthcare reforms, the near future remains clouded by uncertainties and challenges ahead, which are underlined by the unrelenting Chinese economic slowdown.

The ongoing healthcare reform is ambitious but inadequately funded by the government from the start and it is further complicated by an imbalance of financial responsibilities between local and central governments. Excessive financial burdens on local governments compel them to rely excessively on cost containment to finance healthcare reform and lead to premature failures as well as uneven regional implementation of many reform measures across the country.

Despite turbulences and growth rate fallbacks in recent years, most experts continue to agree that China is set to become the second-largest pharmaceutical market by 2020, and ultimately, the largest one in the world.